Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) EBT (2016 - 2025)

Adma Biologics' EBT history spans 13 years, with the latest figure at $61.6 million for Q4 2025.

  • For Q4 2025, EBT rose 77.44% year-over-year to $61.6 million; the TTM value through Dec 2025 reached $182.7 million, up 45.3%, while the annual FY2025 figure was $182.7 million, 45.29% up from the prior year.
  • EBT reached $61.6 million in Q4 2025 per ADMA's latest filing, up from $47.5 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $61.6 million in Q4 2025 to a low of -$18.8 million in Q2 2021.
  • Average EBT over 5 years is $8.9 million, with a median of -$1.9 million recorded in 2023.
  • Peak YoY movement for EBT: decreased 10.0% in 2021, then skyrocketed 1332.71% in 2024.
  • A 5-year view of EBT shows it stood at -$16.5 million in 2021, then rose by 28.55% to -$11.8 million in 2022, then soared by 189.84% to $10.6 million in 2023, then soared by 227.67% to $34.7 million in 2024, then soared by 77.44% to $61.6 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's EBT are $61.6 million (Q4 2025), $47.5 million (Q3 2025), and $40.1 million (Q2 2025).